IMMX ▲ +5.5% - Immix Biopharma, Inc. $IMMX - Immix Biopharma Announces 89% Complete Response Rate at Interim Update Across All NEXICART-2 Patients, with MRD-Negativity Indicating Potential to Reach up to 98% Complete Response Rate, Supporting Potential Best-in-Class Therapy for Relapsed/Refractory AL Amyloidosis 29-SEP-2026 07:01 AM ET